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Abstract:
Objective: To review glucose-lowering efficacy and changes in renal function associated with
GLP-1 receptor agonists and SGLT2-Inhibitors among patients with chronic kidney disease (CKD)
and type 2 diabetes mellitus (T2DM).
Data Sources: A literature search of MEDLINE and Cochrane databases was performed from
2000 to March 2018 using search terms: SGLT2 inhibitors, sodium glucose co-transporter 2,
canagliflozin, empagliflozin, dapagliflozin, glucagon-like peptide-1 receptor agonists, GLP-1,
exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, and chronic kidney
disease. References of identified articles were also reviewed.
Study Selection and Data Extraction: English-language studies investigating glucose-lowering
endpoints and/or changes in renal function with a U.S. approved SGLT2 inhibitor or GLP-1
receptor agonist were included.
Data Synthesis: GLP-1 agonists and SGLT2-Inhibitors effectively lower glucose in patients with
T2DM and CKD. Both agents have demonstrated short-term renoprotective effects by slowing
progression of albuminuria and decreasing urine albumin-to-creatinine values.
Relevance to Patient Care and Clinical Practice: This review highlights the glucose-lowering
efficacy and reported renal benefits of GLP-1 agonists and SGLT2-Inhibitors when used in
patients with T2DM and CKD. Given that these comorbidities are associated with increased
cardiovascular risk, we believe that these agents should be the preferred add-on agents in most
patients with uncontrolled T2DM and CKD.
Conclusions: In patients with T2DM and CKD, GLP-1 agonists and SGLT2-Inhibitors are effective
in lowering glucose, preventing progression of worsening albuminuria, and may reverse the
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level of albuminuria. Ongoing studies will provide additional information as to whether these
agents will become standard of care in treating patients with T2DM and CKD.

Introduction:
Chronic kidney disease (CKD), defined as reduced estimated glomerular filtration rate (eGFR)
and/or presence of increased albuminuria (urinary albumin-to-creatinine ratio >30 mg/g) for at
least 3 months, is a common comorbidity of diabetes mellitus (DM).1 While CKD may result
from multiple etiologies, long-term uncontrolled DM is a major risk factor for diabetic kidney
disease, as well as the most common cause of CKD and the leading cause of end-stage-renal
disease globally.2,3 The most recent estimates from the United States Renal Data System
(USRDS) report that approximately 40% of patients with CKD also have concomitant DM.4
Given that DM and CKD are both associated with increased morbidity and mortality, multiinterventional approaches are recommended to reduce the progression of worsening
albuminuria and kidney dysfunction, as well as lower risk of cardiovascular events. Such
approaches include achieving blood pressure <130/80 mm Hg,1,5 use of angiotensin converting
enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in patients with CKD and
albuminuria, as well as maintaining glycemic control.1,5

Patients with type 2 DM (T2DM) may achieve glycemic control with a combination of oral and
injectable medications. Current standards for treating T2DM recommend choosing additional

5

antihyperglycemic therapies based on several patient-specific factors, including efficacy of
lowering hemoglobin A1C (A1C), cost, risk of hypoglycemia, and potential for weight gain.
Metformin remains the preferred first agent for most patients with T2DM due to effective A1Clowering, low hypoglycemia risk, neutral weight gain, and low cost. Metformin is primarily
renally eliminated, thus contraindicated in patients with an eGFR <30 ml/min/1.73m2.5 In
patients with T2DM and CKD, renal function must also be considered as many of the available
second-line antihyperglycemic agents require dose reduction in the setting of reduced renal
function, or are not recommended for continued use in patients with eGFR <45 ml/min/1.73m2
(Table 1).

Recent cardiovascular outcomes trials (CVOT) have reported reduced risk of major
cardiovascular events with select oral antihyperglycemic agents. Trials evaluating sodiumglucose co-transporter-2 inhibitors (SGLT2-I) empagliflozin and canagliflozin, and glucagon-like
peptide-1 receptor agonist (GLP-1RA), liraglutide, each reported reduced risk of a primary
composite endpoint of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke
compared to placebo when added to standard antihyperglycemic treatment in patients with
T2DM.6–8 Each trial included a subset of patients with CKD and reported on prespecified renal
outcomes, although not as a primary study endpoint. In the EMPA-REG trial,6 26% of patients
had an eGFR <60 ml/min/1.73m2 and nearly 40% had some degree of albuminuria. Compared to
placebo, empagliflozin was associated with a 38% reduction in progression to
macroalbuminuria and 44% reduction in doubling serum creatinine. In the CANVAS studies8,
30.2% had some degree of albuminuria, the majority defined as microalbuminuria. Improved
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renal outcomes associated with canagliflozin included a 27% reduced risk of albuminuria
progression, and lower risk of a composite renal outcome including consistent 40% reduction in
eGFR, need for renal replacement therapy, or renal death. Regression of albuminuria also
occurred more frequently in those who received canagliflozin compared to placebo. Lastly, the
LEADER7 trial included 21% of subjects with eGFR 30-59 ml/min/1.73m2, and even included a
small sample of patients (2.4%) with eGFR<30 ml/min/1.73m2. The composite renal endpoint of
new macroalbuminuria or doubling of serum creatinine with eGFR <45 ml/min/1.73m2, need
for renal replacement therapy, or renal death was reduced by 22% in subjects who received
liraglutide vs placebo, but occurred at relatively low rates in each group (1.5% vs 1.9%,
respectively).

Given that canagliflozin, empagliflozin, and liraglutide all demonstrated lower risk of major
cardiovascular events, as well as potential improvements in renal outcomes, these agents may
be preferred therapies in patients with T2DM and CKD. The objective of this article is to review
available evidence assessing the efficacy and potential renoprotective effects of SGLT2-I and
GLP-1RAs in patients with CKD and T2DM.

Methods
Data Sources
A search was conducted using PubMed and Cochrane databases to identify studies from 2000
to March 7, 2018 pertaining to the safety and efficacy of SGLT2-I and GLP-1RA among patients
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with CKD. Mesh terms and keywords used in the search included, “SGLT2 inhibitors”, “sodium
glucose co-transporter 2”, “canagliflozin”, “empagliflozin”, “dapagliflozin”, “Glucagon-Like
Peptide-1 Receptor/agonists”, “GLP-1”, “exenatide”, “liraglutide”, “albiglutide”, “dulaglutide”,
“lixisenatide”, “semaglutide”, “kidney disease”, and “chronic kidney disease”. PubMed search
filters were applied for English language, humans, and adults aged ≥18 years. References of
identified articles were reviewed to identify any additional studies not found in the initial
search. In order to limit results to only clinical trials, the search filter for clinical queries was
applied.9 Article selection and screening process is depicted in Figure 1.

Study Selection
Studies were included if they reported outcomes related to glucose-lowering efficacy and/or
renal endpoints for U.S. approved SGLT2-I or GLP-1RA in a study population of T2DM and CKD,
defined as an eGFR <60 ml/min and/or urine albumin-to-creatinine ratio >30 mg/g (or
equivalent). Pre-post studies were eligible if they reported baseline and follow up changes.
Trials including patients with CKD and normal kidney function could be considered if full data
for the CKD population was presented separate from the study population as a whole.
Secondary analysis of a CKD populations from primary trials were also eligible. Published
abstracts, editorials, and letters to the editor were not included in this review.
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Results
Potential articles were reviewed by three authors (MK, JL, AH) to determine eligibility. Eight
studies met our inclusion criteria and are summarized in Table 2. Three studies evaluated
liraglutide, while five studies evaluated SGLT2-I (canagliflozin, dapagliflozin, and empagliflozin).

Of the eight included studies, all but one was a randomized-control trial10. Five studies
employed a placebo group against active treatment (SGLT2-I or GLP-1RA)11–15, one study
compared SGLT2-I or to glimepiride treatment16, and one study compared GLP-1RA added to
insulin therapy vs insulin therapy alone17. Efficacy of SGLT2-I or GLP-1RA was assessed by
change in A1C in seven studies10–15,17, along with change in fasting plasma glucose in five
studies.11–15 Renal endpoints of change in eGFR were assessed in five studies10,11,13,14,16, and all
eight studies assessed change in urine protein-to-creatinine (UPCR) or urine albumin-tocreatinine ratio (UACR).

Glucagon-like peptide-1 (GLP-1) receptor agonists
Currently there are six GLP-1RA available in the US, including exenatide, liraglutide, lixisenatide,
dulaglutide, semaglutide, and albiglutide. GLP-1RA lower glucose by several mechanisms,
including increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying,
and increasing satiety. All GLP-1RA are indicated as an adjunct to diet and exercise to improve
glycemic control in adults with T2DM. Liraglutide now carries an additional indication for
reduced risk of major cardiovascular events in adults with T2DM and clinical cardiovascular
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disease. Renal dose adjustment is not required for most GLP-1RA, except exenatide and
lixisenatide (Table 1). Exenatide is not indicated in patients with eGFR <30mL/min/1.73m2,
while lixisenatide should not be used in patients with eGFR <15mL/min/1.73m2.5

Efficacy and Renal Effects of GLP-1RA in Patients with CKD
The Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in
Patients With T2DM and Moderate Renal Impairment (LIRA-RENAL) trial evaluated liraglutide
efficacy and safety over a 26-week period when added on to existing antihyperglycemic therapy
in patients with uncontrolled T2DM and moderate renal impairment11. This double-blind,
placebo-controlled trial included 279 patients with a mean age approximately 67 years and an
A1C of ~8%. Patients were randomized to daily liraglutide or placebo subcutaneous injection.
Approximately 43% of patients in each group had an eGFR 30-44 mL/min/1.73m2, 56% of
patients had an eGFR of 45-59 mL/min/1.73m2, and mean UACR was 55.5 mg/g for the
liraglutide group and 69.8 mg/g for the placebo group. The primary endpoint was change in
baseline A1C to week 26; changes in fasting plasma glucose (FPG) from baseline to week 26
were also assessed. After 26 weeks, A1C was reduced -1.05% in the liraglutide group vs. -0.38%
in the placebo group (p<0.0001). Estimated mean change in FPG from baseline to 26 weeks
was -22.0 mg/dL with liraglutide vs. -10.3 mg/dL with placebo (p=0.036). Changes in renal
function (eGFR and UACR) were measured from baseline to 26 weeks. The mean observed
change in eGFR after 26 weeks was -0.35 mL/min/1.73m2 in the liraglutide group versus 0.37
mL/min/1.73m2 in the placebo group, which resulted in an estimated treatment ratio of 0.98
(p=0.36). The ratio of UACR values at week 26 compared to baseline were 0.87 with liraglutide,
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compared to 1.05 with placebo, however this difference was not statistically significant
(p=0.19). The study concluded that liraglutide is effective in improving glycemic control, without
affecting renal function.11

A single-arm study of 23 Japanese patients with T2DM evaluated the A1C-lowering effect and
progression of diabetic nephropathy (DN) and proteinuria following 12-month treatment with
liraglutide.10 Patients had a mean age of 58.2 years, mean A1C of 7.4% at baseline and all
patients had overt DN (defined as UPCR >0.5 g/g) prior to study entry, with baseline UPCR of
2.53 g/g (or 2530 mg/g). No comparator arm was used in this study, rather a pre/post design. A
significant decrease in A1C was observed at all time points. Baseline A1C was reduced from
7.4% to 7.0% after 1 month (p<0.001), 6.6% by month 6 (p<0.001), and 6.9% by month 12
(p<0.05). Baseline UPCR decreased to 1.62 g/g at 1 month (p<0.001), 1.45 g/g at 6 months
(p<0.001), and finally 1.47 g/g at 12 months (p<0.01). The study also found a strong correlation
between baseline proteinuria and changes in proteinuria after 12 months of liraglutide therapy
(r=0.84, p<0.0001). Changes in eGFR were minimal over the 12-month study period, as eGFR
decreased slightly from 58.2 mL/min/1.73m2 at baseline to 56.9 mL/min/1.73m2 after 12
months. Annual rates of eGFR decline were improved with liraglutide, decreasing from -6.6
mL/min/1.73m2/year prior to liraglutide initiation, to -0.33 mL/min/1.73m2/year (p=0.003) after
one year of liraglutide. Thus, with a significant decline in proteinuria and improved eGFR
decline, authors concluded that for patients with T2DM and overt DN, addition of liraglutide is
useful for decreasing A1C as well as slowing the progression of DN.10

11

A third single-center, open-label trial evaluated changes in several cardiometabolic markers,
including albuminuria, with liraglutide in patients with T2DM treated with insulin.17 Seventeen
patients were randomized to either liraglutide titrated up to 0.9 mg/day plus insulin (8 patients)
or insulin treatment only (9 patients). In addition to insulin, patients in each cohort were also
receiving oral antihyperglycemic agents. Mean age was 59 years and a greater proportion of
males (63%) were randomized to receive liraglutide compared to the control group (33%).
Mean eGFR was >60 ml/min/1.73m2 in both groups, but albuminuria was present in both study
cohorts. Mean baseline A1C was 8.2% in the liraglutide group and 7.9% in the placebo group,
and both groups were receiving daily insulin doses of about 0.5 units/kg/day. Mean A1C and
weight were significantly reduced in the liraglutide group after 12, 24, and 36 weeks of
treatment. At week 24, baseline A1C values had fallen from 8.2% to 7.5% in patients receiving
liraglutide compared with an increase from 7.9% to 8.1% in the control group (p=0.0035). No
data on fasting or post-meal plasma glucose were reported. Mean UACR levels at baseline were
220 mg/g in the liraglutide group and 254 mg/g in the control group, consistent with
albuminuria. Compared to placebo, liraglutide was associated with significantly decreased
mean UACR at week 12 (343 mg/g vs 76 mg/g; p=0.050), week 24 (310 mg/g vs 91 mg/g;
p=0.016), and week 36 (226 mg/g vs 32 mg/g; p=0.022). The authors concluded that when
added to baseline insulin therapy in patients with T2DM, liraglutide favorably improves
glycemic control, body weight, inflammatory markers, and albuminuria.17

Sodium-Glucose Co-transporter Type 2 (SGLT2) inhibitors
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Currently four SGLT2-I (canagliflozin, dapagliflozin, empagliflozin, and most recently
ertugliflozin) are approved to improve glucose in adults with T2DM as adjunct to diet and
exercise. As a class, the SGLT2-I increase urinary glucose excretion by blocking the reabsorption
of glucose in the renal proximal tubule. As SGLT2-I exert their effect in the kidneys, there are
specific dose adjustments based upon renal function according to each medication’s prescribing
information (Table 1). Renal function should be assessed prior to initiation of SGLT2-I and
periodically thereafter to ensure adequate renal function. The recommended eGFR range for
continued SGLT2-I use varies among agents, but all are contraindicated when eGFR <30
mL/minute/1.73 m2.5

Efficacy and Renal Effects of SGLT2-I in Patients with CKD
The Efficacy and safety of empagliflozin added to existing anti-diabetes treatment in patients
with T2DM and chronic kidney disease (EMPA-REG-RENAL) trial was a multicentered,
randomized, double-blind, parallel-group trial, designed to assess the efficacy and safety of
empagliflozin in patients with CKD stages 2-4 and T2DM.12 Full efficacy and renal outcomes data
were available for CKD stages 2 (n=290) and 3 (n=374), but not stage 4 (n=74). Patients with
CKD stage 3 (eGFR ≥30 to <60 mL/min per 1.73 m2) were randomized to receive empagliflozin
25 mg or placebo for 52 weeks. Patients in this CKD subgroup had a mean age of 64.9 years,
and baseline eGFR of 44.9 mL/min per 1.73 m2. The primary efficacy endpoint was change in
A1C from baseline to week 24. Changes in FPG, body weight, and BP were also examined as
secondary endpoints. Changes in eGFR and UACR throughout the study were evaluated as
safety endpoints.
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In the stage 3 CKD subgroup, the adjusted mean change in A1C from baseline to week 24 was
-0.42% for empagliflozin 25 mg vs. placebo (p<0.0001). The A1C-lowering effect remained at
week 52, with mean A1C reduction of -0.44% compared to placebo (p<0.0001). Adjusted
treatment differences for empagliflozin vs placebo were also significantly lower for FPG at both
24 weeks (-1.1 mmol/L; p<0.001) and 52 weeks (-0.7 mmol/L; p=0.0037). In addition to reduced
A1C and FPG, there was also a significant decrease in body weight and BP with empagliflozin
versus placebo. Compared to placebo, a greater reduction in UACR from baseline to 52 weeks
was reported with empagliflozin (–183.78 mg/g; p=0.0031). Although not a specified endpoint
of this trial, fewer patients randomized to empagliflozin progressed from normal UACR to
microalbuminuria (UACR 30-299 mg/g) compared to placebo (12.2% vs. 22.2%) and from
microalbuminuria to macroalbuminuria (UACR ≥300 mg/g) (2.0% vs. 11.4%). Additionally, a
greater proportion of patients with baseline macroalbuminuria improved to microabluminuria
with empagliflozin (32.6%) compared to those who received placebo (8.6%). This study was one
of the first trials to report improved glycemic control and improved albuminuria status in
patients with T2DM and CKD.12

A second multicenter placebo-controlled, double-blind clinical trial evaluated the efficacy and
safety of dapagliflozin in patients with T2DM and moderate renal impairment (eGFR 30 to 59
mL/min per 1.73m2) and included a small percentage of patients with eGFR ≥60 mL/min per
1.73m2 (4.4%) and eGFR <30 mL/min per 1.73m2 (4.0%) at baseline. Patients were similar in
baseline characteristics for each study group. Mean age ranged from 66-68 years, and baseline
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A1C differed by study group and ranged from 8.22% to 8.53%. All patients had a mean UACR
>60 mg/g, and over two-thirds of patients had diagnosed DN at baseline. Patients were
randomized to receive dapagliflozin 5 mg, 10 mg, or placebo for at least 24 weeks in addition to
other pre-enrollment antihyperglycemic therapies. Patients who completed the first 24 weeks
of therapy were eligible to continue for an additional 28 weeks, then an additional extension
period of 52 weeks (total of 104 weeks). There were 252 patients randomized, 202 entered the
study for an additional 28 weeks, and 139 patients completed 104 weeks of the extension
period. The primary endpoint was mean change in A1C from baseline to 24 weeks; change in
FPG from baseline to week 24 was also evaluated. At the end of week 24, there was no
statistically significant difference in the mean change in A1C for dapagliflozin 5 mg compared to
placebo (-0.41% vs. -0.32%; p=0.561) or dapagliflozin 10 mg vs placebo (-0.44% vs. -0.32%;
p=0.435). Both doses of dapagliflozin reduced FPG from baseline to 24 weeks more than
placebo, however statistical significance was evaluated. In a post-hoc analysis of baseline CKD
status, dapagliflozin produced a larger reduction in the adjusted A1C change and FPG in
patients with CKD stage 3A compared to stage 3B from baseline to week 24 versus placebo.
Numerically lower reductions in eGFR from baseline to week 24 were reported in the placebo
group (-0.25 mL/min/1.73m2) compared to dapagliflozin 5 mg (-2.38 mL/min/1.73m2) and 10
mg (-4.80 mL/min/1.73m2). By week 104, changes in eGFR were similar between placebo (-2.38
mL/min/1.73m2) and dapagliflozin 5 mg (-1.71 mL/min/1.73m2) and 10 mg (-3.50
mL/min/1.73m2), however no statistical significance was reported for either time period.
Patients receiving dapagliflozin were more likely to experience a shift to a lower UACR category
than patients receiving placebo (22.6% vs. 10.7%). Lastly, fewer patients receiving dapagliflozin
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5 or 10 mg compared to placebo experienced a UACR value >1800 mg/g during the 104-week
treatment (10.8%, 9.5%, and 13.3%, respectively). The results of this trial contrast to those from
the EMPA-REG-RENAL trial in that dapagliflozin did not demonstrate significant A1C-lowering
efficacy among patients with T2DM and CKD. Dapagliflozin did appear to improve UACR more
than placebo, but again was not a primary endpoint of this trial.

Three trials have evaluated the efficacy and safety of canagliflozin in patients with T2DM and
CKD. The first study published in 2013 was a randomized, double-blind, placebo-controlled,
phase 3 trial conducted across 89 centers in 19 countries.14 The study included 269 patients
with T2DM and stage 3 CKD (eGFR ≥30 to <50 mL/min/1.73m2). Patients had a mean age of 68.5
years and A1C of 8.0%. Baseline mean was eGFR 39.4 mL/min/1.73m2 with mean UACR of 30.0
mg/g. Patients were randomized to canagliflozin 100 mg, 300 mg, or placebo daily to assess the
change in A1C at week 26 compared to baseline. Both doses of canagliflozin (100 and 300 mg)
produced a significant reduction in mean A1C from baseline in arms compared to placebo (0.33% vs. -0.03%; p<0.05) and (-0.44% vs. -0.03%; p<0.01), respectively. Changes in FPG from
baseline to week 26 were numerically lower for both canagliflozin 100 vs placebo, although
neither reached statistical significance. Each study group experienced a decrease in eGFR, but
reductions were larger in both the canagliflozin 100 and 300 mg groups compared to placebo
(mean percent changes of -9.1%, -10.1%, and -4.5% respectively). There was also an increase in
blood urea nitrogen (BUN) with both canagliflozin arms compared to placebo. The reductions in
eGFR and increased BUN with canagliflozin arms occurred early and trended back towards
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baseline by week 26. A lower proportion of patients treated with canagliflozin 100 and 300 mg
had a progression of albuminuria from baseline to week 26 compared to placebo (5.1, 8.3, and
11.8% respectively). Lastly, treatment with canagliflozin 100 and 300 mg was associated with
greater median percent reductions in UACR from baseline to week 26 compared to placebo
(-29.9%, -20.9%, and -7.5%, respectively), although no statistical significance was calculated.

As a follow-up extension study, 229 of the 269 patients that completed the first 26 weeks of
therapy continued for an additional 26 weeks to evaluate the efficacy and safety of canagliflozin
at week 52.13 At week 52, changes in A1C from baseline were numerically lower for
canagliflozin 100 mg vs. placebo (-0.19% vs. 0.07%) and canagliflozin 300 mg vs. placebo (0.33% vs. 0.07%). Confidence intervals (95% CI) for calculated differences between canagliflozin
100 mg and 300 mg showed that only canagliflozin 300 mg significantly reduced A1C from
baseline to week 52. Similar to changes in FPG from the 26-week study, changes at 52 weeks
were numerically lower with both doses of canagliflozin but did not achieve statistical
significance. Decreases in eGFR at week 52 were seen with canagliflozin 100 and 300 mg
compared with placebo (–2.1, –4.0 and –1.6 ml/min/1.73m2, respectively). Assessing changes in
UACR from baseline to week 52 showed that placebo was associated with a 19.7% increase in
UACR, compared to a -16.4% decrease with canagliflozin 100 mg and -28.0% with canagliflozin
300 mg. Similar to the results seen at the 26-week time period, the proportion of patients
progressing from normal UACR to albuminuria was lower with canagliflozin 100 and 300 mg
(10.3%, 14.7%, respectively) compared to placebo (17.1%). These two trials provide evidence
that canagliflozin is associated with a clinically relevant A1C reductions, and the potential to
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improve UACR in patients with T2DM and CKD who require additional glucose-lowering
therapy.

The most recent study of canagliflozin in patients with T2DM and CKD was a secondary analysis
of a previous multicentered clinical trial of patients randomized to either canagliflozin 100 or
300 mg daily or glimepiride titrated up to 8 mg daily. Data for a subgroup of patients (n=230)
with UACR ≥30 mg/g at baseline was reported separate from the overall study cohort. Baseline
characteristics for the CKD subgroup were similar to the overall study group. Mean age ranged
from 55.6 to 58.5 years, and baseline A1C was 7.9% in patients randomized to glimepiride or
canagliflozin 100 mg, and 8.0% in the canagliflozin 300 mg group. Mean eGFR at baseline
ranged from 86.5 to 91.1 ml/min/1.73m2, similar to the overall study population. Mean UACR
varied between the study groups of the CKD patients, with the lowest UACR (56.5 mg/dL) in
canagliflozin 100 mg group and the highest UACR value (75.2 mg/dL) in the canagliflozin 300
mg group. Endpoints reported separately for this subgroup of CKD patients included 30%
decline in eGFR and percent reduction in UACR over a 2-year period. No data on A1C-lowering
between glimepiride and canagliflozin groups were reported for the CKD subgroup. However, in
the CKD subgroup, significant reductions in UACR from baseline were reported with
canagliflozin 100 mg (-31.7%;P=0.01) and canagliflozin 300 mg (-49.3%; p<0.001) versus
glimepiride. Additionally, decline in eGFR was measured during the 2-year trial period. In
patients with baseline UACR >30 mg/g, calculated hazard ratios (HR) for 30% eGFR decline were
lower for canagliflozin 100 mg (HR=0.37; p=0.03) and canagliflozin 300 mg (HR=0.69; p=0.33)
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versus glimepiride. This trial provides evidence that canagliflozin may be more effective in
slowing progression of DN compared to glimepiride.

Currently, the Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes
in Participants With Diabetic Nephropathy (CREDENCE) clinical trial is prospectively evaluating
renal and cardiovascular endpoints with canagliflozin vs placebo in patients with T2DM and CKD
stage 2 or 3 with UACR >300 mg/g, already treated with maximally tolerated ACE-i or ARB.
(NCT02065791). This trial’s primary composite endpoint is time to first occurrence of end-stage
kidney disease (ESKD), doubling of serum creatinine, renal or cardiovascular death. Expected
trial duration is 5.5 years.18

Relevance to Patient Care and Clinical Practice
Current standard of care for preventing progression of CKD includes controlling BP and glucose,
as well as use of renin-angiotensin inhibitors. Several oral and injectable antihyperglycemic
agents are available to improve glucose in patients with T2DM. Current standards of care
promote a patient-centered approach when selecting additional glucose-lowering medication,
considering risk of hypoglycemia, weight gain, adverse effects, and most recently cardiovascular
and renal effects.5 Cardiovascular outcomes trials have reported reduced cardiovascular risk
with liraglutide, canagliflozin, and empagliflozin and reported positive changes in composite
renal endpoints, although in a predominately non-CKD population. Whether the cardiovascular
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or renal benefits of these medications translate to patients with CKD has not been
prospectively evaluated in long-term clinical trials.

Our literature review identified eight studies that reported efficacy and/or assessment of renal
changes in patients with CKD and T2DM. Available studies suggest that in patients with CKD,
both GLP-1RA and SGLT2-I are associated with A1C reductions similar to patients without CKD.
A recent meta-analysis of 38 randomized controlled trials including nearly 24,000 patients with
T2DM treated with one of three SGLT2-I (canagliflozin, dapagliflozin, or empagliflozin) reported
significant A1C reductions of -0.6% to -0.9%, compared to placebo.19 Similarly, a meta-analysis
of available GLP-1RA included 34 trials and over 14,000 patients with T2DM reported that GLP1RA have the ability to lower A1C -0.55% to -1.21% versus placebo.20 From our review, there is
evidence that liraglutide and several SGLT2-I positively impact albuminuria either by reducing
UACR in patients with micro- or macroalbuminuria, or by preventing progression to
albuminuria. Both liraglutide and the SGLT2-I studied produce a small decrease in eGFR
compared to baseline, which may not be clinically significant. This small decrease in eGFR
would likely be outweighed by the positive renal effects of preventing or reversing albuminuria.

The precise mechanism by which SGLT2-I and GLP-1RA exert their potentially renoprotective
benefits is currently unknown. Potential mechanisms for improving albuminuria may be
multifactorial, including: increased natriuresis, reduced intraglomerular pressure, reduced renal
hyperfiltration, as well as pleiotropic effects such as anti-inflammatory effects.21,22 Both
antihyperglycemic classes have been shown to inhibit a sodium-hydrogen exchanger protein
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(NHE3) located in the proximal tubule, which may be responsible for the natriuretic effect and
excreting excess sodium.21,22 While tight glucose control is associated with reduced risk for
developing diabetic nephropathy, it is unlikely that the renal benefits of SGLT2-I and GLP-1RA
are entirely due to glucose lowering. Studies as short as 26 weeks demonstrated improvements
in albuminuria despite minimal A1C reductions. Even in long-term CVOT, the improvement in
glycemic control was modest, and not likely to be the sole contributor to improving renal
outcomes or reducing cardiovascular risk. While both GLP-1RA and SGLT2-I are also associated
with reductions in body weight and BP, these effects are modest and may not fully explain the
cardiovascular and renal benefits seen reported in our review. Perhaps the culmination of
reduced glucose, BP, natriuresis, and anti-inflammatory effects lead to the observed
improvements in albuminuria.

Regardless of the mechanism, these agents have demonstrated glucose-lowering and improved
albuminuria effects in patients with T2DM and CKD. Additionally, long-term CVOTs trials have
reported reduced cardiovascular risk in patients at high risk of cardiovascular disease. While not
without potential adverse effects, we believe that GLP-1RA and SGLT2-I should become firstline agents (in addition to renin-angiotensin inhibitors) in patients with T2DM and CKD, a
population at increased risk for CV mortality. Ongoing clinical trials prospectively evaluating
SGLT2-I will provide definitive information regarding renoprotective benefits in patients with
T2DM and CKD, already receiving standard of care. A meta-analysis of available data assessing
positive albuminuria changes effects of SGLT2-I and GLP-1RA would be a valuable endeavor.
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Conclusion
Our review highlights that both SGLT2-I and GLP-1RA can be used in patients with T2DM and
CKD to improve glycemic control. Three SGLT2-I and the GLP-1RA liraglutide reduced A1C and
improved or prevented albuminuria in patients with CKD and T2DM. Current ADA standards
now recommend consideration of renal effects when choosing antihyperglycemic therapy in
patients with T2DM and note benefits of three agents on progression to diabetic nephropathy.
Prospective trials are needed to confirm the observed renoprotective effects in patients with
CKD and T2DM. If future trials are successful, SGLT2-I and/or GLP-1RA should join reninangiotensin inhibitors as recommended treatment in patients with uncontrolled T2DM and CKD
to slow progression of diabetic kidney disease.
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Table 1: Renal dose adjustments for antihyperglycemic agents
Biguanides
eGFR 30-44
Metformin

Do not initiate
Consider 50% dose reduction if
previously treated

eGFR <30

Use is contraindicated

CrCl ≥30-59

12.5 mg daily

CrCl ≥15-29

6.25 mg daily

DPP4-inhibitors

Alogliptin

ESRD (CrCl <15 or
requiring

6.25 mg daily

hemodialysis)
eGFR <45
Saxagliptin

ESRD requiring
hemodialysis

Sitagliptin

2.5 mg daily
2.5 mg daily

eGFR ≥30-44

50 mg daily

eGFR <30

25 mg daily

ESRD requiring
hemodialysis or

25 mg daily

peritoneal dialysis
SGLT2-Inhibitors
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eGFR 45-59
Canagliflozin

eGFR ≥30-44
eGFR<30

Dapagliflozin

eGFR 30-59
eGFR <30

Empagliflozin

eGFR 30-44
eGFR<30

Ertugliflozin

eGFR 30-59
eGFR <30

100 mg daily (maximum dose)
Do not initiate
Discontinue if eGFR persistently <45
Use is contraindicated
Do not initiate
Discontinue if eGFR persistently <60
Use is contraindicated
Do not initiate
Discontinue if eGFR persistently <45
Use is contraindicated
Do not initiate
Discontinue if eGFR persistently <60
Use is contraindicated

GLP-1 receptor agonists
Exenatide
Lixisenatide

CrCl <30 or ESRD

Use not recommended

eGFR <15

Use not recommended

Alpha-glucosidase inhibitor
Acarbose

eGFR <30

Use not recommended

Miglitol

eGFR <25

Use not recommended

CrCl= creatinine clearance (ml/min); eGFR= estimated glomerular filtration rate
(ml/min/1.73m2); ESRD = end-stage renal disease.
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Figure 1: Study selection flowchart
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Table 2: Summary of trials of GLP-1 Receptor agonists and SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
Baseline renal
Study

Study design

Number

function (eGFR-

Study

Treatment

Efficacy (change in

Renal endpoints

of pts

mL/min/1.73m2) or

duration

groups

A1C)

assessed

Change in A1C from

Estimated ratio of

UACR)
GLP1 Receptor Agonists
Baseline eGFR:
Randomized,

Liraglutide: 45.4

double-

ml/min/1.73m2

Davies et

blind, and

al. 2016

placebocontrolled

279

Placebo: 45.5
ml/min/1.73m2

tiral

baseline to week 26: eGFR at week 26 to

26 weeks

Liraglutide

Liraglutide vs

titrated up

placebo:

to 1.8 mg

baseline:

Liraglutide and

daily versus

(-1.05% vs.

placebo (0.99 vs.

placebo

-0.38%; p<0.0001)

1.01; p=0.36)

Baseline UACR:

1

Liraglutide: 55.5 mg/g

Change in FPG

Estimated ratio of

Placebo: 69.8 mg/g

(mg/dL) from

UACR at week 26 to

baseline to week 26: baseline:

Imamura,
et al.
2013

Baseline eGFR:

Nonrandomized,

Single arm

58.2

Liraglutide

ml/min/1.73m2
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12 months
Baseline UPCR:
2.53 g/g

Liraglutide vs.

Liraglutide and

placebo (-22.0 vs.

placebo (0.87 vs.

-10.3; p=0.036)

1.05; p=0.19)

Change in A1C from

Change in annual

baseline to 12

eGFR decline

months:

(ml/min/1.73m2)
before and after 12

0.3mg/d
titrated up

7.4% to 6.9%

to 0.9 mg/d

(p=0.035).

months treatment:

-6.6 to -0.33
(p=0.003)

2

Change in urinary
protien (g/g Cr) from
baseline to 12
months:
2.53 to 1.47
(p=0.0015)

Bouchi, et Singleal. 2017

17

All patients had eGFR

36 weeks

Insulin

Change in A1C from
Change in UACR from

center,

>60, but UACR >200

treatment

baseline to week 24:

randomized,

mg/g at baseline:

(control) vs.

liraglutide vs. control baseline to week 24:

insulin +

(-0.7% vs. +0.2%;
p=0.035)

open-label,
comparative

Liraglutide: 220 mg/g

liraglutide

trial

Control: 254 mg/g

0.3 mg/d

liraglutide vs. control

3

titrated to

(-129 mg/g vs. +56

0.9 mg/d

mg/g; p=0.016)

(liraglutide)
SGLT2 inhibitor trials
Kohan et

Randomized, 252

Baseline eGFR 30-59

24 weeks

Dapagliflozin

Change in A1C from

Mean change in

al. 2014

double-

ml/min/1.73m2 in

(some

5 or 10 mg

baseline to week 24: eGFR

91.7% of all study

patients

vs. placebo

(ml/min/1.73m2)

blind,

(139

placebo-

completed patients

completed

Dapagliflozin 5 mg

from baseline to

controlled

104 weeks

up to 104

vs. placebo

week 24: (No p-

trial

of

Baseline UACR:

weeks)

(-0.41% vs.

value reported)

extension

Dapagliflozin (5 or 10

period)

mg): 73-79 mg/g
Placebo: 67 mg/g

-0.32%; p=0.561)
Dapagliflozin 5 mg vs.
Dapagliflozin 10 mg

placebo

vs. placebo (-0.44%

(-2.38 vs. -0.25)

vs. -0.32%; p=0.435)

4

Dapagliflozin 10 mg
vs. placebo
(-4.80 vs. -0.25)
Change in FPG
(mg/dL) from
baseline to 24

Proportion of

weeks:

patients experienced

(No p-value

UACR >1800 mg/g

reported):

during 104-week
treatment period:

Dapagliflozin 5 mg

(No p-value reported)

vs. placebo
(-5.2 vs. 8.4)

Dapagliflozin 5 mg
(10.8%)
Dapagliflozin 10 mg

5

Dapagliflozin 10 mg

(9.5%)

vs. placebo

Placebo

(-0.6 vs. 8.4)

(13.3%)

Number of patients
shifting to lower
UACR category at
week 104:
Dapagliflozin: 22.6%
Placebo: 10.7%

Yale et al.

Randomized, 269

Baseline eGFR:

2013

double-

39.4 ml/min/1.73m2

26 weeks

Canagliflozin
100 or 300

6

blind,
placebo-

Baseline UACR:

controlled

30.0 mg/g

trial

mg vs.

Change in A1C from

Change in eGFR

placebo

baseline to week 26: (ml/min/1.73m2)
from baseline to
Canagliflozin 100 mg

week 26: (No p-value

vs. placebo

reported)

(-0.33% vs. -0.03%;
p<0.05)

Canagliflozin 100 mg
vs. placebo

Canagliflozin 300 mg

(-3.6 vs. -1.4)

vs. placebo
(-0.44% vs. -0.03%;

Canagliflozin 300 mg

p<0.001)

vs. placebo
(-3.9 vs. -1.4)

7

Change in FPG

Percent reduction in

(mg/dL) from

UACR from baseline

baseline to week 26: to week 26:
(No p-values
Canagliflozin 100 mg

reported)

vs. placebo
(-11.7 vs. 0.5; p=NS)

Canagliflozin 100 mg
vs. placebo

Canagliflozin 300 mg

(-29.9% vs. -7.5%)

vs. placebo
(-14.9 vs. 0.5; p=NS)

Canagliflozin 300 mg
vs. placebo
(-20.9% vs. -7.5%)

8

Proportion of
patients progressing
from normal UACR
to albuminuria from
baseline to week 26:
(No p-value reported)

Canagliflozin 100 mg
(5.1%)
Canagliflozine 300 mg
(8.3%)
Placebo (11.8%)

9

Yale et al.

Extension of

2014

Yale et al.

229

Baseline eGFR:

52 weeks

Canagliflozin

Change in A1C from

39.4 ml/min/1.73m2

(26-week

100 or 300

baseline to week 52: (ml/min/1.73m2)

extension

mg vs.

Baseline UACR:

of

placebo

30.0 mg/g

previous

vs. placebo

Yale et al.

(-0.19% vs. 0.07%;

Canagliflozin 100 mg

2013

95% CI, -0.53 to

vs. placebo

study)

0.001)

(-2.1 vs. -1.6; 95% CI,

2013 study

Change in eGFR

from baseline to
Canagliflozin 100 mg

week 52:

-2.8 to 1.7)
Canagliflozin 300 mg
vs. placebo

Canagliflozin 300 mg

(-0.33% vs. 0.07%;

vs. placebo

95% CI, -0.68 to -

(-4.0 vs. -1.6;

0.14)

95% CI, -4.6 to -0.3)

10

Change in FPG

Percent change in

(mmol/L) from

UACR from baseline

baseline to week 52: to week 52:
(No p-value reported)
Canagliflozin 100 mg
vs. placebo

Canagliflozin 100 mg

(-0.1 vs. 0.5;

vs. placebo

95% CI, -1.5 to 0.2)

(-16.4% vs. 19.7%)

Canagliflozin 300 mg

Canagliflozin 300 mg

vs. placebo

vs. placebo

(-0.3 vs. 0.5;

(-28.0% vs. 19.7%)

95% CI, -1.7 to 0.1)

11

Proportion of
patients progressing
from normal UACR
to albuminuria from
baseline to week 52:

Canagliflozin 100 mg
(10.3%)
Canagliflozine 300 mg
(14.7%)
Placebo (17.%)

Heerspink Secondary

230

Baseline eGFR:

2 years

Canagliflozin

Change in A1C for

subgroup with UACR 30% decline in eGFR

et al.

analysis of

86.5-91.1

100 or 300

2017

patients

ml/min/1.73m2

mg vs.

Hazard ratio (HR) for

12

with UACR

glimepiride

≥30 mg/g not

(canagliflozin vs.

reported

glimepiride):

≥30 mg/g

Baseline UACR:

titrated up

enrolled in

Canagliflozin 100 mg:

to 8 mg

previous

56.5 mg/g

randomized
trail

Canagliflozin 100 mg:
HR=0.37; p=0.03

Canagliflozin 300 mg:
75.2 mg/g

Canagliflozin 300 mg:
HR=0.69; p=0.33

Glimepiride:
60.1 mg/g
Percent reduction in
UACR (canagliflozin
vs. glimepiride):

Canagliflozin 100 mg:

13

-31.7% (p=0.01)

Canagliflozin 300 mg:
-49.3% (p<0.001)

Barnett

Randomized, 374

Baseline eGFR (Stage

et al.

double-

patients

3 CKD patients):

25 mg or

2014

blind,

with CKD

44.9 ml/min/1.73m2

placebo

placebo-

stage 3

52 weeks

Empagliflozin Change in A1C from

Change in UACR

baseline to week 24: (mg/g) from baseline
to week 52:
Empagliflozin vs.

controlled

placebo

Empagliflozin vs.

trial

(-0.37% vs. 0.05;

placebo

p<0.0001)

(-183.8; p=0.0031);

Included
subgroups of

Change in A1C from

patients

baseline to week 52:

14

Proportion of

with CKD 2-4
(subgroup

Empagliflozin vs.

patients progressing

analysis

placebo

from normal UACR

available for

(-0.32% vs. 0.12;

to microalbuminuria:

each CKD

p<0.0001)

(No p-value reported)

stage)
Empagliflozin vs.
Change in FPG

placebo (12.2% vs.

(mmol/L) from

22.2%)

baseline to week 24:
Proportion of
Empagliflozin vs.

patients progressing

placebo

from

(-0.5 vs. 0.6;

microalbuminuria to

p<0.0001)

macroalbuminuria:

15

(No p-value reported)
Change in FPG
(mmol/L) from

Empagliflozin vs

baseline to week 52: placebo (2.0% vs.
11.4%)
Empagliflozin vs.
placebo
(-0.4 vs. 0.3;
p=0.0037)
A1C= hemoglobin A1C; CKD= chronic kidney disease; eGFR= estimated glomerular filtration rate; FPG= fasting plasma glucose; UACR=
Urinary albumin-to-creatinine ratio; UPCR= Urine protein-to-creatinine ratio
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